MYOS Co. (NASDAQ:MYOS) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $1.56 and traded as high as $1.48. MYOS shares last traded at $1.48, with a volume of 173 shares trading hands.
Separately, ValuEngine lowered shares of MYOS from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th.
The firm’s 50-day simple moving average is $1.56 and its 200-day simple moving average is $1.47. The company has a quick ratio of 1.21, a current ratio of 2.74 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $13.39 million, a PE ratio of -3.29 and a beta of 0.78.
MYOS (NASDAQ:MYOS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). MYOS had a negative net margin of 603.47% and a negative return on equity of 93.90%. The business had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.14 million. On average, equities research analysts forecast that MYOS Co. will post -0.5 earnings per share for the current year.
An institutional investor recently raised its position in MYOS stock. Community Capital Management Inc. grew its position in shares of MYOS Co. (NASDAQ:MYOS) by 295.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 142,452 shares of the company’s stock after acquiring an additional 106,392 shares during the period. Community Capital Management Inc. owned about 1.55% of MYOS worth $217,000 as of its most recent SEC filing. 5.94% of the stock is owned by hedge funds and other institutional investors.
MYOS Company Profile (NASDAQ:MYOS)
MYOS RENS Technology Inc, a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
Featured Article: Technical Indicators – What is a Golden Cross?
Receive News & Ratings for MYOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS and related companies with MarketBeat.com's FREE daily email newsletter.